Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Propofol fumarate tenofovir (TAF) in decompensated hepatitis B cirrhosis
ChiCTR2100045599Phase 4Recruiting
- Sponsor
- Traditional Chinese Medicine Hospital Affiliated to Xinjiang Medical University
- Start
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of tenofovir alafenamide in hepatitis B-related liver cirrhosis, sponsored by Traditional Chinese Medicine Hospital Affiliated to Xinjiang Medical University. Primary endpoint: Highly sensitive HBV DNA at 48 weeks. Started Apr 2021; status: recruiting.
02
Drugs
tenofovir alafenamide
03
Conditions
hepatitis B-related liver cirrhosis
Beyond the preview
Go deeper on ChiCTR2100045599.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100045599.